Skip to main content
CVIR Endovascular

Table 5 Effect of embolic agent on UFS-QoL symptom score and HRQL score

From: Randomised trial of two embolic agents for uterine artery embolisation for fibroids: Gelfoam versus Embospheres (RAGE trial)

 

Embospheres

Gelfoam

Difference between groups (E-G)***

Baseline*

6 months*

Change**

Baseline*

6 months*

Change**

Symptom score

64 (18)

23 (16)

−41 (−56 to − 25) p < 0.001

54 (15)

32 (26)

−22 (− 36 to − 8) p = 0.01

−14 (− 34 to 6) p = 0.15

HRQL

41 (28)

79 (20)

38 (13 to 63) p = 0.01

53 (19)

78 (21)

25 (9 to 41) p = 0.01

2 (−18 to 22) p = 0.84

  1. *Mean (SD)
  2. **Mean of change over time calculated as 6 month – baseline, 95% CI of change, p-value
  3. ***Mean difference between embolic agents at 6 months adjusted for baseline values, 95% CI of difference. Positive values indicate higher results in the E group
Back to article page